STX-478
Phase 1/2- Indications
- Breast cancer, Solid tumors
Company intelligence / Profile preview
Scorpion Therapeutics
Boston, Massachusetts, USAscorpiontx.com ↗
- Ownership
- Private
- Employees
- ~121
- Development stage
- Phase 1
01
Overview
STX-478 (PI3Kα inhibitor) is in Phase 1/2 trials showing promising monotherapy results with dose response in HR+/HER2- metastatic breast cancer. PFL-241/STX-241 (EGFR inhibitor) has begun Phase 1/2 trials for non-small cell lung cancer with first patient dosed in October 2024.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Beyond the preview
Go deeper on Scorpion Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Scorpion Therapeutics.